Aurinia Pharmaceuticals Inc. balance sheet AUPH

Annual Quarterly

As of Sep 30, 2026, Aurinia Pharmaceuticals Inc. had total assets of $825.7 million and total liabilities of $168.2 million. Total assets were up 56.5% from a year earlier. Stockholders' equity was $657.5 million. It held $45.8 million in cash and investments against $58.7 million of total debt, net debt of $12.9 million. The current ratio, current assets divided by current liabilities, was 6.12.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017
Assets
Cash	46 -37.2%	80 -3.9%	83 +71.1%	49 -48.2%	94 -59.4%	232 -14.9%	272 -11.0%	306 +159.4%	118 -28.8%	166
Cash and investments	46 -37.2%	80 -3.9%	83 -76.2%	351 -9.9%	389 -12.8%	447 +64.0%	272 -11.0%	306 +159.4%	118 -28.8%	166
Inventory	44 -2.4%	46 +16.5%	39 -1.2%	40 +60.4%	25 +28.1%	19 +38.8%	14	—	—	—
Total current assets	588 +34.0%	492 +10.2%	447 +5.1%	425 -4.0%	443 -13.8%	513 +22.4%	419	—	—	—
Property and equipment, net	2 -23.3%	2 -22.7%	3 -18.6%	3 -8.1%	4 -17.4%	4 -7.7%	5	—	—	—
Total assets	826 +56.5%	752 +36.5%	551 +0.5%	548 +16.4%	471 -13.3%	543 +17.2%	464 +43.0%	324 +122.3%	146 -23.2%	190
Liabilities and equity
Accounts payable	3 +36.1%	3 -36.1%	5	—	—	—	—	—	—	—
Total current liabilities	96 +26.0%	94 -4.1%	98 +26.7%	77 +67.4%	46 +13.4%	41 +27.0%	32	—	—	—
Total liabilities	168 +4.0%	170 -1.7%	173 +1.8%	170 +160.0%	65 +1.8%	64 +15.0%	56 +117.5%	26 -22.8%	33 +38.1%	24
Stockholders' equity	658 +79.8%	581 +54.0%	377 -0.1%	378 -6.8%	405 -15.4%	479 +17.5%	408	—	—	—
Debt
Lease liabilities	59 -25.0%	75 -5.7%	79 -18.7%	98 +1106.8%	8 -7.4%	9 +3.9%	8	0	—	—
Total debt	59 -25.0%	75 -5.7%	79 -18.7%	98 +1106.8%	8 -7.4%	9 +3.9%	8	0	—	—
Net cash	-13 -141.8%	5 +32.8%	4 -98.4%	253 -33.6%	381 -12.9%	438 +65.9%	264 -13.7%	306	—	—
Ratios
Current ratio	6.12x	5.25x	4.57x	5.50x	9.60x	12.63x	13.11x	—	—	—
Debt to equity	0.09x	0.13x	0.21x	0.26x	0.02x	0.02x	0.02x	—	—	—
Debt to EBITDA	0.33x	0.60x	5.38x	—	—	—	—	—	—	—
Return on equity	47.80%	49.40%	1.52%	-20.64%	-26.68%	-37.77%	-25.18%	—	—	—
Return on assets	38.06%	38.21%	1.04%	-14.24%	-22.97%	-33.30%	-22.15%	—	—	—
Book value per share	4.91	4.39	2.68	2.63	2.85	3.38	3.22	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: AUPH (Nasdaq)
Fiscal year ends: December 31
Headquarters: Edmonton, Alberta, Canada
SEC filer status: Large accelerated filer
SEC CIK: 1600620

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.